ETF Holdings Breakdown of VKTX

VKTX institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-20	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	36,396	USD 1,228,365 0.6%
2025-10-20	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	273	USD 9,214
2025-10-20	IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF)	955	USD 32,231
2025-10-20	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	79,331	USD 2,677,421
2025-10-20	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	549	USD 18,529
Total =		117,504	USD 3,965,760

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with VKTX

Brokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) PT at $87.50

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has been given a consensus recommendation of “Buy” by the thirteen brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating on the company. The […] - 2025-09-17 02:42:45

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of “Buy” by Analysts

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has received a consensus rating of “Buy” from the fourteen research firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to […] - 2025-08-20 02:40:58

Viking Therapeutics Announces Positive Data From Phase 2 VENTURE Study

(RTTNews) - Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, Tuesday announced positive top-line results from its Phase 2 VENTURE study of the oral tablet formulation of VK2735, the company's drug candidate for the treatment of obesity. The study met - 2025-08-19 08:45:56

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 13.5% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 30,446 shares of the biotechnology company’s stock after acquiring an additional 3,611 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in […] - 2025-08-06 04:56:58

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by Cetera Investment Advisers

Cetera Investment Advisers increased its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 67.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 144,349 shares of the biotechnology company’s stock after purchasing an additional 58,168 shares during the […] - 2025-08-05 05:20:49

Kestra Private Wealth Services LLC Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Kestra Private Wealth Services LLC raised its position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 15.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,828 shares of the biotechnology company’s stock after purchasing an additional 1,176 shares during the quarter. Kestra […] - 2025-07-29 04:40:49

Brokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Target Price at $87.15

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has been given a consensus rating of “Buy” by the fourteen research firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the […] - 2025-07-04 02:40:47

Viking Therapeutics (NASDAQ:VKTX) Given Buy Rating at HC Wainwright

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $102.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 262.09% from […] - 2025-06-27 02:19:02

Stock Traders Purchase High Volume of Call Options on Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Traders acquired 23,521 call options on the stock. This is an increase of 45% compared to the average daily volume of 16,210 call options. Analyst Ratings Changes A number of equities research analysts recently issued reports […] - 2025-06-11 02:28:43

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Parallel Advisors LLC

Parallel Advisors LLC boosted its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 64.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,363 shares of the biotechnology company’s stock after purchasing an additional 536 shares during the period. Parallel […] - 2025-06-10 04:46:49

Public Employees Retirement System of Ohio Raises Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Public Employees Retirement System of Ohio lifted its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,547 shares of the biotechnology company’s stock after buying an […] - 2025-06-02 05:38:58

Deutsche Bank AG Reduces Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Deutsche Bank AG lowered its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 70.4% during the fourth quarter, HoldingsChannel reports. The fund owned 6,427 shares of the biotechnology company’s stock after selling 15,284 shares during the period. Deutsche Bank AG’s holdings in Viking Therapeutics were worth $259,000 as of its most recent SEC […] - 2025-06-02 04:52:52

Northern Trust Corp Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Northern Trust Corp raised its position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 11.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 535,984 shares of the biotechnology company’s stock after purchasing an additional 54,871 shares during the period. Northern Trust Corp’s holdings in Viking Therapeutics were worth $21,568,000 as of […] - 2025-05-13 05:31:00

Dimensional Fund Advisors LP Sells 10,394 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Dimensional Fund Advisors LP trimmed its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 9.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 100,762 shares of the biotechnology company’s stock after selling 10,394 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Viking Therapeutics were worth $4,055,000 at […] - 2025-05-13 04:38:46

NewEdge Advisors LLC Increases Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

NewEdge Advisors LLC raised its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 108.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 2,068 shares of the biotechnology company’s stock after purchasing an additional 1,076 shares during the period. NewEdge Advisors LLC’s holdings in Viking Therapeutics were worth $83,000 at the […] - 2025-05-04 05:42:49

1 Beaten-Down Stock to Buy and Hold for 10 Years

Viking Therapeutics (NASDAQ: VKTX) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of fa - 2025-05-01 06:47:00

Mariner LLC Purchases 4,161 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Mariner LLC grew its position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 40.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,426 shares of the biotechnology company’s stock after purchasing an additional 4,161 shares during the period. […] - 2025-05-01 05:23:00

Marshall Wace LLP Acquires 2,256 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Marshall Wace LLP grew its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 12.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 20,114 shares of the biotechnology company’s stock after purchasing an additional 2,256 shares during the period. Marshall Wace LLP’s holdings […] - 2025-05-01 04:51:01

Truist Financial Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

Truist Financial reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a report released on Monday, Marketbeat.com reports. The firm currently has a $75.00 target price on the biotechnology company’s stock, down from their previous target price of $95.00. A number of other analysts have also recently weighed in on […] - 2025-04-29 05:14:56

Rockefeller Capital Management L.P. Sells 10,387 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Rockefeller Capital Management L.P. decreased its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 30.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,636 shares of the biotechnology company’s stock after selling 10,387 shares during the period. Rockefeller Capital […] - 2025-04-22 05:47:04

Invesco Ltd. Sells 3,376 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Invesco Ltd. decreased its position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 0.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 872,846 shares of the biotechnology company’s stock after selling 3,376 shares during the period. Invesco Ltd. owned about 0.78% of Viking Therapeutics worth […] - 2025-04-17 06:35:01

Wells Fargo & Company MN Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Wells Fargo & Company MN raised its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 36.1% during the 4th quarter, Holdings Channel reports. The firm owned 261,635 shares of the biotechnology company’s stock after purchasing an additional 69,355 shares during the quarter. Wells Fargo & Company MN’s holdings in Viking Therapeutics were worth […] - 2025-04-17 05:45:00

Viking Therapeutics Sees Unusually High Options Volume (NASDAQ:VKTX)

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) saw unusually large options trading on Tuesday. Stock traders purchased 30,549 call options on the stock. This is an increase of 90% compared to the average volume of 16,040 call options. Wall Street Analyst Weigh In Several analysts recently issued reports on the stock. Maxim Group reduced […] - 2025-04-15 04:42:50

Schroder Investment Management Group Has $2.39 Million Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Schroder Investment Management Group trimmed its position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 39.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,994 shares of the biotechnology company’s stock after selling 39,592 shares during the […] - 2025-04-07 05:11:01

Vanguard Group Inc. Acquires 4,827 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Vanguard Group Inc. grew its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 0.0% in the 4th quarter, HoldingsChannel reports. The firm owned 10,172,441 shares of the biotechnology company’s stock after buying an additional 4,827 shares during the quarter. Vanguard Group Inc. owned about 0.09% of Viking Therapeutics worth $409,339,000 as of its […] - 2025-04-03 04:30:46

American Century Companies Inc. Increases Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

American Century Companies Inc. boosted its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 9.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 301,582 shares of the biotechnology company’s stock after acquiring an additional […] - 2025-04-02 04:54:53

Xponance Inc. Buys 610 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Xponance Inc. boosted its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 4.5% in the fourth quarter, Holdings Channel reports. The firm owned 14,024 shares of the biotechnology company’s stock after acquiring an additional 610 shares during the period. Xponance Inc.’s holdings in Viking Therapeutics were worth $564,000 as of its […] - 2025-03-26 07:16:51

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by Arizona State Retirement System

Arizona State Retirement System lifted its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,929 shares of the biotechnology company’s stock after acquiring an additional 353 shares during […] - 2025-03-14 06:10:54

HC Wainwright Reaffirms “Buy” Rating for Viking Therapeutics (NASDAQ:VKTX)

HC Wainwright restated their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $102.00 target price on the biotechnology company’s stock. A number of other research firms have also recently weighed in on VKTX. William Blair reaffirmed an […] - 2025-03-12 06:08:49

Viking Therapeutics, Inc. (NASDAQ:VKTX) Stock Position Reduced by New York Life Investment Management LLC

New York Life Investment Management LLC lessened its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 7.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,097 shares of the biotechnology company’s stock after selling 881 shares […] - 2025-03-05 08:46:56

Back to Listing

Disclaimer